ArticleFrontiers in endocrinology2025
Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: A subset of patients with differentiated thyroid cancer and lung metastases (DTC-LM) may progress to radioiodine-refractory (RAIR) disease, which is associated with a poor prognosis. This study aimed to investigate the clinical outcomes and potential risk factors associated with RAIR disease in DTC-LM patients. Methods: 177 DTC-LM patients who underwent radioiodine (RAI) therapy at our center were retrospectively analyzed. Clinicopathological profiles were compared between the RAI-avid (RAIA) and RAIR groups. Univariate and multivariate regression analyses were conducted to identify risk factors for RAIR status and progressive disease (PD). Results: Overall, 80 patients were included in the RAIR group, accounting for 45.2% of the total patients. Multivariate analysis revealed that older age and higher T stage were independent risk factors for RAIR disease. Age≥55 years (HR: 2.975, 95% CI: 1.424 -6.218, P = 0.004), RAI-avid status (HR: 4.315, 95% CI: 1.753 - 10.622, P = 0.001) and the ps-Tg≥528.5ng/mL (HR: 3.665, 95% CI: 1.656 - 8.107, P = 0.001)were identified as independent predictors of PD. Kaplan-Meier analysis revealed a lower progression-free survival (PFS) rate in the RAIR group than in the RAIA group (P< 0.001). Conclusion: RAIR disease is common among DTC-LM patients and is associated with adverse clinical outcomes. Age, RAI avidity status, and ps-Tg levels serve as important predictors of PD. Early risk stratification and individualized management strategies are crucial to improving outcomes in DTC-LM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.